CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction
CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction
Background:
Coronary artery disease causes plaque in arteries. This can cause stroke or heart disease. Drugs called statins might shrink plaque. Researchers want to study how CT scanning can determine if an individuals arterial plaque has decreased while taking statins.
Objectives:
To measure the change in coronary artery plaque volume in people treated with high-intensity statin therapy using CT and MRI scans. To study the metabolic activity of plaque in arteries. To determine how well plaque measurements from heart CT scans can be replicated.
Eligibility:
Men ages 40-75 and women ages 40-75 who are good candidates for statin treatment
Design:
Visit 1: participants will be screened with:
Participants will begin high-intensity statin treatment.
Participants will have 7 more visits over 3 years. All visits include blood tests and medication review. Some may also include:
Participants may join the PET Substudy. This includes 5 more visits during the study. These include:
Participants may join the Reproducibility Substudy if they had a slow heart rate during their first CT scan. This includes 1 additional heart CT scan 4 weeks later.
In high risk patients undergoing invasive angiography, intravascular ultrasound (IVUS) has shown reduction of plaque for patients treated with HMG-CoA reductase inhibitors (statins). However, there is no accepted noninvasive method to determine if treatment for atherosclerosis results in reduction of coronary artery plaque.
Coronary artery CT angiography (CCTA) is noninvasive and can accurately determine the degree of coronary artery stenosis. In addition, the extent of calcified and noncalcified plaque may be directly measured using this technology at low radiation dose using state-of-the-art CT scanners. Several retrospective studies have previously suggested that CCTA may be able to show plaque regression in the coronary arteries due to statin therapy.
The primary aim of this proposal is to determine the change in coronary artery plaque volume in individuals treated with high intensity statin therapy as defined by 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.
Men and women who meet the inclusion and exclusion criteria will undergo CCTA examination for the presence or absence of coronary artery plaque. Individuals with evidence of noncalcified coronary plaque by CCTA and who meet criteria for HMG-CoA reductase (statin) therapy will be evaluated for a total of 36 months. The change of coronary artery plaque (progression or no change, or regression) in individuals with noncalcified plaque at baseline will be measured by CCTA at yearly intervals.
A. Men greater than or equal to 40 and less than or equal to 75 years of age; women greater than or equal to 40 and less than or equal to 75 years of age
B. Willing to travel to the NIH for follow-up visits.
C. Willing to start or modify statin therapy.
D. Able to understand and sign informed consent.
E. Eligible for primary prevention statin therapy
(http://www.mesa-nhlbi.org/calcium/input.aspx).
EXCLUSION CRITERIA:
A. Allergy or prior clinically relevant adverse reaction to Rosuvastatin (does not include minor muscle pain).
B. High intensity statin treatment for more than 90 days prior to enrollment
C. LDL greater than or equal to 190 mg/ml
D. Physician-diagnosed heart attack
E. Physician-diagnosed stroke or TIA
F. Physician-diagnosed heart failure
G. Having undergone procedures related to cardiovascular disease (CABG, angioplasty, valve replacement, pacemaker or defibrillator implantation, any surgery on the heart or arteries)
H. Active treatment for cancer
I. Prior hypersensitivity reaction to iodinated contrast injection
J. Known hyperthyroidism.
K. Acute renal failure, renal transplant, dialysis and renal failure clinically diagnosed.
L. History of liver transplant or severe liver disease or unexplained elevation of baseline ALT>3x upper limit of normal
M. Pregnancy and nursing
N. Mental, neurologic or social condition preventing understanding of the rationale, procedures, risks and potential benefits associated with the trial.
O. Any other conditions that precludes safety for MRI and/or CT imaging per the researcher's evaluation.
P. Individuals with hemoglobinopathies or severe asthma.
Q. Severe renal excretory dysfunction, estimated glomerular filtration (eGFR) rate < 30 mL/min/1.73m2 body surface area according to the Modification of Diet in Renal Disease criteria Glomerular filtration rate will be estimated using the MDRD 2005 revised study formula: eGFR (mL/min/1.73m2) = 175 x (standardized serum creatinine)-1.154 x (age)-0.203 x 0.742 (if the subject is female) or x 1.212 (if the subject is black)